# Cryo-Cell International, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Cryo-Cell International, Inc).

## Overview

Cryo-Cell International is a U.S.-based cellular processing and cryogenic storage company focused on preserving umbilical cord blood and cord tissue stem cells for families, public transplant use, and related biostorage applications. Founded in 1989, it was the first private cord blood bank to separate and store stem cells in 1992 and has built a long operating history in newborn stem cell banking. The company also manufactures and sells its PrepaCyte® CB processing system, which is used in cord blood processing. In addition to its family banking business, Cryo-Cell is expanding into third-party cold storage through ExtraVault and is developing cellular therapy capabilities at its Durham, North Carolina facility.

## Products & services

• Private cord blood and cord tissue banking
• Public cord blood banking services
• PrepaCyte® CB Processing System
• ExtraVault biorepository and cold storage services
• Cellular therapy and MSC laboratory capabilities

- **Family cord blood and cord tissue banking** (85%) — Collection, processing, and long-term cryogenic storage of newborn cord blood and cord tissue for private family use.
- **Public cord blood banking** (2%) — Processing and storage of cord blood stem cells for public transplant use through registry-linked programs.
- **Processing technology and product sales** (1%) — Sales of PrepaCyte® CB processing systems and related product revenue tied to cord blood processing technology.
- **Third-party biostorage and biorepository services** (12%) — ExtraVault cold storage services for biopharma companies, healthcare institutions, and other external customers.

- Private cord blood and cord tissue banking
- Public cord blood banking services
- PrepaCyte® CB Processing System
- ExtraVault biorepository and cold storage services
- Cellular therapy and MSC laboratory capabilities

## Customers

Cryo-Cell's core customers are expectant parents who enroll newborns in private cord blood and cord tissue banking programs to preserve a potential future medical resource for the child or family members. A significant portion of new enrollments comes from returning customers and referrals, which indicates that trust, brand reputation, and service quality are important purchase drivers. The company also serves public transplant infrastructure through its public cord blood banking activity, where units are listed on the NMDP registry for use by transplant centers. Through ExtraVault, Cryo-Cell is also targeting biopharmaceutical companies and healthcare institutions that need secure, cost-effective biologic, reagent, vaccine, and specimen storage. These customer groups buy for different reasons, but all depend on Cryo-Cell's handling expertise, regulated storage environment, and long-duration custody model.

- **Private family banking customers** (primary) — Expectant parents who purchase cord blood and cord tissue collection, processing, and multiyear storage for potential future family medical use.
- **Public transplant network** (secondary) — Registry-linked transplant centers and public health users that rely on publicly banked cord blood units for stem cell transplantation.
- **Biopharma and healthcare storage clients** (emerging) — Third-party pharmaceutical companies and medical institutions that buy ExtraVault cold storage and inventory management services.
- **Technology and processing customers** (emerging) — Customers and partners associated with PrepaCyte® CB processing technology and related product sales.

- Expectant parents buying private newborn stem cell storage for family use
- Returning customers and referrals that support repeat enrollment growth
- Transplant centers and registry users accessing public cord blood units
- Biopharma companies needing cold storage for biologics, reagents, and vaccines
- Healthcare institutions outsourcing biorepository and specimen storage
- Customers seeking long-duration storage contracts and regulated handling

## Geography

Cryo-Cell is headquartered in Oldsmar, Florida, and its U.S.-based business operations, including processing and storage, are handled from there and from its storage facility in Durham, North Carolina. The Durham site is strategically important because it houses the company's cryogenic storage capacity and supports the planned ExtraVault biostorage expansion. The company also markets cord blood stem cell programs through license agreements in Central America, including Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama. Its public units are listed on the NMDP registry, which connects to major international registries and broadens access beyond the U.S. market. Geography matters because the business is operationally concentrated in the United States while also exposed to regulatory, commercial, and execution risks in licensed international markets.

- Headquartered in Oldsmar, Florida, where executive and operating functions are based
- Primary processing and cryogenic storage operations are in Durham, North Carolina
- U.S. market is the core source of private banking enrollments and storage revenue
- Central America is served through license agreements in six countries
- Public cord blood units are connected to the NMDP registry and international networks
- Geographic concentration in the U.S. makes operations sensitive to domestic regulation

## Strategy

Cryo-Cell's strategy is to defend its core private cord blood banking franchise while using its long operating history and accreditations to differentiate on quality and trust. The company is also trying to broaden its addressable market by monetizing its Durham facility through ExtraVault, which targets third-party cold storage demand from biopharma and healthcare customers. Another strategic priority is to leverage its existing stem cell expertise into adjacent cellular therapy capabilities, including mesenchymal stromal cell manufacturing from cord tissue. Management also continues to rely on online advertising, field educators, referrals, and registry relationships to support new enrollments and retention. These priorities matter because the core family-banking market is competitive and mature, so adjacent services and facility utilization can diversify revenue and improve asset productivity.

- **Expand ExtraVault biostorage services** (short-term) — This creates a new revenue stream from the Durham facility and reduces reliance on the family banking market.
- **Grow private cord blood and cord tissue enrollments** (short-term) — The core business depends on new family enrollments and recurring storage contracts.
- **Develop adjacent cellular therapy capabilities** (medium-term) — MSC manufacturing and related lab services could extend the company's stem cell platform into higher-value applications.

- Protect the core private cord blood and cord tissue banking franchise
- Use AABB and FACT accreditations to support quality-based differentiation
- Expand ExtraVault third-party cold storage to monetize facility capacity
- Develop cellular therapy and MSC manufacturing capabilities from cord tissue
- Drive enrollments through online advertising, field educators, referrals, and repeat customers
- Use registry connectivity to support public banking relevance and transplant access
- Leverage existing infrastructure to diversify beyond family banking

## Risks

Cryo-Cell faces concentration risk because most of its business depends on continued demand for newborn cord blood and cord tissue banking, a market that is competitive and sensitive to consumer awareness. The company also faces execution risk in scaling ExtraVault and other adjacent services, since these initiatives require customer adoption, operational reliability, and effective utilization of the new Durham facility. Management has highlighted regulatory risk around stem cell storage facilities, which can affect compliance costs and operating flexibility. The company also discloses cybersecurity and third-party hosting risk because it stores healthcare and customer data on external systems, and a breach could damage trust and create legal exposure. More generally, the business is exposed to macroeconomic pressure, consumer spending trends, and the possibility of NYSE American delisting if listing standards are not maintained.

- **Competitive pressure in private cord blood banking** [high] — The company competes with roughly 25 other national private cord blood banks, which can pressure pricing and enrollment growth.
- **Regulatory changes for stem cell storage facilities** [high] — Management cites increased government regulation as a factor that could limit operations or raise compliance costs.
- **Cybersecurity and third-party hosting breaches** [high] — Stored healthcare and proprietary data could be exposed through external systems, creating legal, financial, and reputational damage.
- **Strategic transaction or spinoff uncertainty** [medium] — Management notes uncertainty around maximizing shareholder value through a strategic transaction or spinoff of Celle Corp.
- **NYSE American listing compliance** [medium] — Failure to meet continued listing standards could lead to delisting and reduce liquidity and investor confidence.

- Dependence on private cord blood enrollment growth in a competitive market
- Regulatory changes affecting stem cell storage facilities and compliance costs
- Execution risk in scaling ExtraVault and other new services
- Cybersecurity and third-party hosting risk for healthcare and customer data
- Macroeconomic weakness could reduce consumer willingness to buy long-duration storage
- Potential NYSE American delisting if continued listing standards are not met
- Public banking demand can be volatile and uneven quarter to quarter

## Accounting

Cryo-Cell's most important accounting judgments center on revenue recognition for long-duration storage contracts, because many customers prepay or sign multiyear agreements and revenue is recognized over the contract life. That creates deferred revenue balances and makes timing of recognition important for comparing quarterly results. The company also highlights allowance for doubtful accounts, stock-based compensation, income taxes, and license and revenue-sharing agreements as critical estimates, all of which can materially affect reported earnings. Public cord blood banking and product revenue can be volatile, so quarter-to-quarter results may shift based on enrollment timing, customer demand, and the mix of processing versus recurring storage fees. Investors should also watch how facility expansion and new service lines are capitalized and depreciated, since those decisions affect margins and future expense recognition.

- **Revenue recognition on storage contracts** — Affects deferred revenue, quarterly comparability, and reported growth rates
- **Allowance for doubtful accounts** — Can change net revenue and operating profit
- **License and revenue-sharing agreements** — Can affect reported revenue mix and margins
- **Stock-based compensation** — Impacts SG&A and earnings quality

- Deferred revenue from multiyear storage contracts affects timing of revenue recognition
- Recurring storage fees versus new specimen processing can shift quarterly revenue mix
- Allowance for doubtful accounts can affect reported receivables and earnings
- Stock-based compensation impacts operating expense and non-cash earnings dilution
- License and revenue-sharing agreements require judgment in allocating revenue
- Facility and equipment depreciation affects margins as Durham capacity is utilized
- Public banking revenue can be volatile and less predictable than private storage

---

*Last updated: 2026-08-11T04:46:27.202750+00:00*